← Eichor
Condition: Resectable Pancreatic Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Resectable Pancreatic Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Phase 2 · 1 location(s) · Zhejiang Provincial People's Hospital · NCT06722911EUS Procedures Using RIVOS™ EUS Access Device
Phase N/A · 1 location(s) · Orlando Health, Inc. · NCT07696572Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for
Phase 2 · 1 location(s) · Ningbo Medical Center Lihuili Hospital · NCT07542002Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Morten Ladekarl · NCT05841420Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
Phase N/A · 1 location(s) · Englewood Hospital and Medical Center · NCT06937996Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Phase 1/Phase 2 · 4 location(s) · Amsterdam UMC, location VUmc · NCT06384560The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreati
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05802394A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Ashish Manne · NCT05624918Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With P
Phase 1/Phase 2 · 1 location(s) · Smartwise Sweden AB · NCT07575191Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NA · 3 location(s) · Varian, a Siemens Healthineers Company · NCT05764720Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy
Phase N/A · 1 location(s) · University of Thessaly · NCT06935448Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · Jinling Hospital, China · NCT06326736Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
NA · 1 location(s) · Minia University · NCT07022015A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Phase 3 · 1 location(s) · Sahlgrenska University Hospital · NCT06714604Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Phase 3 · 1 location(s) · Minia University · NCT07081360Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Ri
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07436741The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05802407Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Phase 2 · 1 location(s) · Loma Linda University · NCT03492671Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Phase N/A · 1 location(s) · Emory University · NCT06595160Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal
Phase 2 · 1 location(s) · Mayo Clinic · NCT05518903Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NA · 1 location(s) · British Columbia Cancer Agency · NCT06574620A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy f
Phase 1/Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06758544Adjuvant Pancreatic Therapy Guided by MRD
NA · 1 location(s) · Ruijin Hospital · NCT06966440A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06944106Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05462496
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.